129 related articles for article (PubMed ID: 9421075)
1. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison.
Jones MW; Kounelis S; Hsu C; Papadaki H; Bakker A; Swalsky PA; Finkelstein SD
Int J Gynecol Pathol; 1997 Oct; 16(4):354-60. PubMed ID: 9421075
[TBL] [Abstract][Full Text] [Related]
2. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
3. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
4. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
8. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
9. The origin and molecular characterization of adenoid basal carcinoma of the uterine cervix.
Jones MW; Kounelis S; Papadaki H; Bakker A; Swalsky PA; Finkelstein SD
Int J Gynecol Pathol; 1997 Oct; 16(4):301-6. PubMed ID: 9421067
[TBL] [Abstract][Full Text] [Related]
10. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
12. [Genetic alterations and transformations in development and establishment of uterine endometrial carcinomas].
Inoue M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Aug; 45(8):751-62. PubMed ID: 8371006
[TBL] [Abstract][Full Text] [Related]
13. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma.
Ohkouchi T; Sakuragi N; Watari H; Nomura E; Todo Y; Yamada H; Fujimoto S
Am J Obstet Gynecol; 2002 Aug; 187(2):353-9. PubMed ID: 12193924
[TBL] [Abstract][Full Text] [Related]
15. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma.
Visscher DW; Yadrandji S; Tabaczka P; Kraut M; Sarkar FH
Diagn Mol Pathol; 1997 Feb; 6(1):64-9. PubMed ID: 9028739
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
18. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
[TBL] [Abstract][Full Text] [Related]
19. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
20. Novel method for simultaneous analysis of p53 and K-ras mutations and p53 protein expression in single histologic sections.
Yamashita K; Yoshida T; Shinoda H; Okayasu I
Arch Pathol Lab Med; 2001 Mar; 125(3):347-52. PubMed ID: 11231481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
